Stock VRPX VIRPAX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Delayed Nasdaq
Other stock markets
 17:33:53 29/04/2024 BST 		5-day change 1st Jan Change
2.85 USD -8.06% Intraday chart for Virpax Pharmaceuticals, Inc. -13.64% -10.97%
03-26 Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-15 Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research
Virpax Pharmaceuticals Stockholders Approve Reverse Stock Split Plan; Shares Fall
Virpax Pharmaceuticals Announces Leadership Transition
Virpax Pharmaceuticals, Inc. Announces CEO Changes
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review
Virpax Names Gerald Bruce as CEO of Novvae Pharmaceuticals Unit
Novvae Pharmaceuticals Announces Executive Appointments
Altasciences von Virpax ausgewählt, um die Entwicklung eines neuen Medikaments zur Verhinderung der Ausbreitung von grippeähnlichen Viren zu unterstützen
Altasciences choisi par Virpax pour soutenir le développement d'un nouveau médicament pour empêcher la propagation de virus apparentés à la grippe
Virpax Pharmaceuticals, Inc Announces the Formation of Novvae? Pharmaceuticals
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method
Virpax Pharmaceuticals Files Patent For Envelta Product Candidate
Top Premarket Gainers
Virpax Pharmaceuticals Names New CFO
Virpax Pharmaceuticals, Inc. Announces Executive Changes
Virpax Pharmaceuticals, Inc. Appoints Barbara Ruskin as Class I Director
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRPX Stock
  4. News Virpax Pharmaceuticals, Inc.
  5. Other languages